Dowling & Yahnke LLC Mirati Therapeutics, Inc. Transaction History

Dowling & Yahnke LLC

$215 Million
Q3 2022

A detailed history of Dowling & Yahnke LLC transactions in Mirati Therapeutics, Inc. stock. As of the latest transaction made, Dowling & Yahnke LLC holds 7,900 shares of MRTX stock, worth $0. This represents 0.26% of its overall portfolio holdings.

Number of Shares

7,900

Holding current value

% of portfolio

0.26%

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 02, 2022	BUY	$59.5 - $86.7 $470,050 - $684,930	7,900 New	7,900 $552,000
Q1 2022 May 04, 2022	SELL	$75.82 - $150.97 $144,058 - $286,843	-1,900 Closed	0 $0
Q4 2021 Feb 10, 2022	BUY	$132.01 - $190.29 $250,818 - $361,551	1,900 New	1,900 $279,000
Q4 2019 Jan 27, 2020	SELL	$70.76 - $128.86 $304,268 - $554,098	-4,300 Closed	0 $0
Q3 2019 Oct 29, 2019	SELL	$77.91 - $109.6 $77,910 - $109,600	-1,000 Reduced 18.87%	4,300 $335,000

Q1 2019 Apr 30, 2019	BUY	$43.65 - $78.95 $231,345 - $418,435	5,300 New	5,300 $388,000

Others Institutions Holding MRTX

# of Institutions

Shares Held

3.57M

Call Options Held

Put Options Held

36.6K

View Full List

About Mirati Therapeutics, Inc.

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

More about MRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Dowling & Yahnke LLC, based on Form 13F filings with the SEC.

News

Stay updated on Dowling & Yahnke LLC with notifications on news.

Account